Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents.

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
How to Treat MDS without Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia  Sonali.
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
HLA-Haploidentical T Cell–Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia  Marco Zecca, Luisa Strocchio, Daria.
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,
Ephraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller 
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.
Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children  Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest  Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.
Biology of Blood and Marrow Transplantation
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies  Stefan O. Ciurea, Richard.
A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide.
Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Mats Remberger, Johan Törlén, Olle.
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia  Ho Joon.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia  Yu Wang,
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation  Karim E. Abou-Nassar, Haesook.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children  Xiaojun.
Blood and Marrow Transplant Handbook
Biology of Blood and Marrow Transplantation
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.
Treatment versus Transplant for Challenging Hematologic Disorders
Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus,
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Presentation transcript:

Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study  Massimo Berger, Edoardo Lanino, Simone Cesaro, Marco Zecca, Elena Vassallo, Maura Faraci, Massimiliano De Bortoli, Veronica Barat, Arcangelo Prete, Franca Fagioli  Biology of Blood and Marrow Transplantation  Volume 22, Issue 5, Pages 902-909 (May 2016) DOI: 10.1016/j.bbmt.2016.02.002 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Immunologic reconstitution after PTCy haplo-HSCT. (A) CD3+CD4+/μL. (B) CD3+CD8+/μL. (C) CD19+/μL. (D) CD3-CD56+/μL. Biology of Blood and Marrow Transplantation 2016 22, 902-909DOI: (10.1016/j.bbmt.2016.02.002) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Rates of 1-year OS and PFS for all patients given PTCy. Biology of Blood and Marrow Transplantation 2016 22, 902-909DOI: (10.1016/j.bbmt.2016.02.002) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Rates of 1-year RI for patients given PTCy haplo-HSCT. N indicates number of patients; E, events. Biology of Blood and Marrow Transplantation 2016 22, 902-909DOI: (10.1016/j.bbmt.2016.02.002) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.